Reducing bias in open-label trials where blinded outcome assessment is not feasible: Strategies from two randomised trials

Trials

Volumn 15, Issue 1, 2014, Pages

  Kahan, Brennan C ^a   Cro, Suzie ^b   Doré, Caroline J ^b   Bratton, Daniel J ^c   Rehal, Sunita ^b   Maskell, Nick A ^d   Rahman, Najib ^e   Jairath, Vipul ^f  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e Oxford Centre for Respiratory Medicine   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bias; Open label; Randomised controlled trial; Subjective outcome; Unblinded outcome assessment; Unmasked

Indexed keywords

ARTICLE; BLEEDING; BLINDED OUTCOME ASSESSMENT; CONTROLLED STUDY; DECISION MAKING; FEASIBILITY STUDY; FOLLOW UP; GASTROINTESTINAL TRACT EXAMINATION; HEALTH CARE PLANNING; HUMAN; INTERNAL EXAMINATION; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT REFERRAL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REDUCING BIAS; RESOURCE ALLOCATION; SYMPTOMATOLOGY; UNITED KINGDOM; UPPER GASTROINTESTINAL BLEEDING; VOMITING; BIOASSAY; DRAINAGE; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL HEMORRHAGE; METHODOLOGY; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; PROCEDURES; RECURRENT DISEASE; STATISTICAL BIAS; TIME; TREATMENT OUTCOME;

BIAS (EPIDEMIOLOGY); DRAINAGE; ENDPOINT DETERMINATION; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL HEMORRHAGE; HUMANS; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; RECURRENCE; REFERRAL AND CONSULTATION; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84934271780     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-456     Document Type: Article

References (22)

1. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D: SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013, 346:e7586. 10.1136/bmj.e7586.
2. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995,273(5):408-412. 10.1001/jama.1995.03520290060030.
3. Schulz KF, Grimes DA: Blinding in randomised trials: hiding who got what. Lancet 2002,359(9307):696-700. 10.1016/S0140-6736(02)07816-9.
4. Boutron I, Tubach F, Giraudeau B, Ravaud P: Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials. J Clin Epidemiol 2004,57(6):543-550. 10.1016/j.jclinepi.2003.12.010.
5. Wright S, Duncombe P, Altman DG: Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex (R)) in people with multiple sclerosis: a new approach. Trials 2012, 13:189. 10.1186/1745-6215-13-189.
6. Hrobjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, Ravaud P, Brorson S: Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 2012, 344:e1119. 10.1136/bmj.e1119.
7. Linde K, Witt CM, Streng A, Weidenhammer W, Wagenpfeil S, Brinkhaus B, Willich SN, Melchart D: The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain 2007,128(3):264-271. 10.1016/j.pain.2006.12.006.
8. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R: The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 1994,44(1):16-20. 10.1212/WNL.44.1.16.
9. Poolman RW, Struijs PA, Krips R, Sierevelt IN, Marti RK, Farrokhyar F, Bhandari M: Reporting of outcomes in orthopaedic randomized trials: does blinding of outcome assessors matter? J Bone Joint Surg Am 2007,89(3):550-558. 10.2106/JBJS.F.00683.
10. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA: Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008,336(7644):601-605. 10.1136/bmj.39465.451748.AD.
11. Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, Als-Nielsen B, Balk EM, Gluud C, Gluud LL, Ioannidis JP, Schulz KF, Beynon R, Welton NJ, Wood L, Moher D, Deeks JJ, Sterne JA: Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 2012,157(6):429-438. 10.7326/0003-4819-157-6-201209180-00537.
12. Hrobjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, Ravaud P, Brorson S: Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. CMAJ 2013,185(4):E201-E211. 10.1503/cmaj.120744.
13. Hrobjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Rasmussen JV, Hilden J, Boutron I, Ravaud P, Brorson S: Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. Int J Epidemiol 2014,43(3):937-948. 10.1093/ije/dyt270.
14. Dechartres A, Boutron I, Roy C, Ravaud P: Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal. J Clin Epidemiol 2009,62(7):695-702. 10.1016/j.jclinepi.2008.09.011.
15. Tudur Smith C, Hickey H, Clarke M, Blazeby J, Williamson P: The trials methodological research agenda: results from a priority setting exercise. Trials 2014,15(1):32. 10.1186/1745-6215-15-32.
16. Jairath V, Kahan BC, Gray A, Dore CJ, Mora A, Dyer C, Stokes EA, Llewelyn C, Bailey AA, Dallal H, Everett SM, James MW, Stanley AJ, Church N, Darwent M, Greenaway J, Le Jeune I, Reckless I, Campbell HE, Meredith S, Palmer KR, Logan RF, Travis SP, Walsh TS, Murphy MF: Restrictive vs liberal blood transfusion for acute upper gastrointestinal bleeding: rationale and protocol for a cluster randomized feasibility trial. Transfus Med Rev 2013,27(3):146-153. 10.1016/j.tmrv.2013.04.001.
17. Kahan BC, Jairath V, Murphy MF, Dore CJ: Update on the transfusion in gastrointestinal bleeding (TRIGGER) trial: statistical analysis plan for a cluster-randomised feasibility trial. Trials 2013, 14:206. 10.1186/1745-6215-14-206.
18. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K: A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009,62(5):464-475. 10.1016/j.jclinepi.2008.12.011.
19. Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007,26(11):2389-2430. 10.1002/sim.2712.
20. Dresler CM, Olak J, Herndon JE 2nd, Richards WG, Scalzetti E, Fleishman SB, Kernstine KH, Demmy T, Jablons DM, Kohman L, Daniel TM, Haasler GB, Sugarbaker DJ: Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005,127(3):909-915. 10.1378/chest.127.3.909.
21. Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C, Graupera I, Poca M, Alvarez-Urturi C, Gordillo J, Guarner-Argente C, Santalo M, Muniz E, Guarner C: Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013,368(1):11-21. 10.1056/NEJMoa1211801.
22. Feagan BG, Sandborn WJ, D'Haens G, Pola S, McDonald JW, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV Jr, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG: The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013,145(1):149-157.e2. 10.1053/j.gastro.2013.03.025.